4 recruiting. 3 Phase 3, 1 Phase 4.
By phase and status
Follow Dr. Inge Winter: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure Clozapine, Esketamine Nasal Product, Escitalopram - Schizophrenia and Related Disorders, Major Depressive Disorder | Phase 3 | Recruiting | Dr. Inge Winter | 1254 | 2025-04-27 | 2026-01-22 |
The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. Escitalopram, Sertraline, Venlafaxine - Bipolar Depression | Phase 3 | Recruiting | Dr. Inge Winter | 418 | 2025-02-11 | 2025-09-26 |
The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. Esketamine Nasal Product, Ketamine Hydrochloride, Esketamine hydrochloride - Major Depressive Disorder, Treatment Resistant Depression | Phase 3 | Recruiting | Dr. Inge Winter | 418 | 2024-08-31 | 2025-09-26 |
The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. Clozapine, Second-line Antipsychotics (treatment as usual) - Schizophrenia and Related Disorders, Early Treatment-Resistance | Phase 4 | Recruiting | Dr. Inge Winter | 418 | 2024-08-01 | 2025-09-26 |
Conditions studied
Bipolar Disorder (2) · Depressive Disorder, Major (2) · Schizophrenia (2) · Depressive Disorder, Treatment-Resistant (1) · Psychotic Disorders (1)
Interventions
Bupropion (2) · Clozapine (2) · Escitalopram (2) · Ketamine (2) · Lithium (2) · Quetiapine Fumarate (2) · Sertraline (2) · Venlafaxine Hydrochloride (2) · Therapeutics (1)
Countries
Austria (3) · Germany (3) · Italy (3) · Spain (3) · United Kingdom (3) · Greece (2) · Israel (1)
Results publications
PMID 41401709
NIH funding
2023 (3)